Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and Ppara -null mouse livers
Toxicological Sciences · 2025
DOI: 10.1093/toxsci/kfaf049 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Toxicological Sciences, 2025. Verfasst von Melissa M Heintz und 5 weiteren Autor:innen. Beteiligte Einrichtung: ToxStrategies LLC, Asheville, NC 28801, United States. Hauptthemen laut MEDLINE: PPAR alpha, Liver, PPAR gamma, Transcriptome. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Chemours Company FC.
Abstract (Originalsprache)
Recent in vitro transcriptomic analyses for short-chain per- and polyfluoroalkyl substances HFPO-DA (ammonium, 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)-propanoate) added to the weight of evidence supporting the peroxisome proliferator-activated receptor alpha (PPARα) activator-induced hepatocarcinogenesis mode of action (MOA) for HFPO-DA-mediated liver effects in rodents. Importantly, PPARα-mediated key events (KEs) including hepatocellular hypertrophy and proliferation that have been shown to occur prior to tumor development in this MOA are rodent-specific and likely not human-relevant. To further inform the MOA of HFPO-DA and evaluate other hypothesized MOAs, phenotypic and transcriptomic responses in wild-type (WT) and Ppara-null mice were investigated following short-term exposure to HFPO-DA or prototypical agonists of PPARα (GW7647), PPARγ (rosiglitazone), or cytotoxicity (acetaminophen). Phenotypic and transcriptomic assessment of mouse livers demonstrated a general lack of response to HFPO-DA or GW7647 exposure in Ppara-null but not WT mice. Conversely, rosiglitazone or acetaminophen elicited similar phenotypic and transcriptomic responses between genotypes demonstrating a lack of PPARα-dependence. In WT mice, HFPO-DA-mediated responses were similar to GW7647 but different from rosiglitazone or acetaminophen. Dose-dependent increases in liver weight, karyomegaly, and mitosis, as well as increased transcriptomic signaling related to PPARα activation and cell proliferation were observed in HFPO-DA and GW7647-exposed WT mice. The consistent phenotypic and transcriptomic signaling patterns between HFPO-DA and GW7647 in WT mice, and the lack of changes in Ppara-null mice, provide further support that HFPO-DA-mediated early KEs in mouse liver are PPARα-dependent, occur via the rodent-specific PPARα MOA, and therefore are not appropriate for use in human health risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ToxStrategies LLC, Asheville, NC 28801, United States.
- ToxStrategies LLC, Austin, TX 78731, United States.
- Hagler Fellow, Texas A&M University, Raleigh, NC 27607, United States.
- ToxStrategies LLC, Katy, TX 77494, United States.
ORCID-Profile: Melissa M Heintz
Förderung
- The Chemours Company FC
Zitieren
APA
Heintz, M. M., Buerger, A. N., Haws, L. C., Cullen, J. M., East, A. W., & Thompson, C. M. (2025). Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and Ppara -null mouse livers. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfaf049
Vancouver
Heintz MM, Buerger AN, Haws LC, Cullen JM, East AW, Thompson CM. Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and Ppara -null mouse livers. Toxicological Sciences. 2025. doi:10.1093/toxsci/kfaf049
BibTeX
@article{Heintz2025,
author = {Heintz, Melissa M and Buerger, Amanda N and Haws, Laurie C and Cullen, John M and East, Alexander W and Thompson, Chad M},
title = {Comparison of phenotypic and transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and Ppara -null mouse livers},
journal = {Toxicological Sciences},
year = {2025},
doi = {10.1093/toxsci/kfaf049}
}
EUVIMED